


Actelion's Finance

Actelion's financial performance for the first quarter of 2008.

Summary


On 22 April 2008, Actelion Ltd announced its financial results for the first quarter of 2008. With total net revenues of CHF 321.6 million (Q107: CHF 290.4 m) and operating expenses of CHF 253.8 million (Q107: CHF 441.9 m), the company reported an operating profit for the first quarter of 2008 of CHF 67.8 million (Q107: operating loss of CHF 151.5 m). Cash EBIT for the same period (excludes employee options, In Process R&D charges and depreciation) amounted to CHF 99.8 million compared to CHF 101.3 million in the first quarter of 2007. The net income for the first quarter of 2008 was CHF 48.3 million (Q107: net loss of CHF 150.0 m). On a fully diluted basis, earnings per share (EPS) for the period were CHF 0.39 compared to a net loss per share of CHF 1.29.

Net revenues



In the first quarter of 2008, Actelion had total revenues of CHF 321.6 million (Q107: CHF 290.4 m), an increase of 11 percent. In local currencies, total product sales increased by 19 percent. Sales of Tracleer® were CHF 287.6 million (Q107: CHF 260.4 m). Ventavis® revenues were CHF 17.4 million, Zavesca® sales amounted to CHF 9.7 million and contract revenues were CHF 6.9 million for the first three months of 2008.


Operating expenses



In the first three months of 2008, operating expenses were CHF 253.8 million (Q107: CHF 441.9 m). In the same period, research and development costs were CHF 85.6 million (Q107: CHF 65.7 m). Selling, general and administration expenses were CHF 121.0 million (Q107: CHF 117.1 m). Cost of sales amounted to CHF 34.1 million (Q107: CHF 29.4 m). Amortization of intangible assets was CHF 4.8 million (Q107: CHF 4.9 m) and an IPRD charge of CHF 8.3 million (Q107: CHF 224.8 m).


Actelion Pharmaceuticals Ltd is a global biopharmaceutical company headquartered in Allschwil/Basel, Switzerland. Actelion concentrates on discovering, developing and marketing innovative drugs for high unmet medical needs. The company is quoted on the SWX Swiss Exchange (tickersymbol: ATLN).

Operating profit/loss




The operating income for the first three months of 2008 amounted to CHF 67.8 million (Q107: operating loss of CHF 151.5 m).

Cash EBIT (Non US GAAP)



In order to better measure the company's performance, Actelion reports Cash EBIT (operating income excluding non-cash items such as employee stock options, amortization and depreciation as well as In Process R&D charges). Cash EBIT for the first three months of 2008 amounted to CHF 99.8 million (Q107: CHF 101.3 m). In local currencies, Cash EBIT increased by twelve percent.

Net profit/loss



In the first three months of 2008, Actelion's net income amounted to CHF 48.3 million (Q107: CHF net loss of CHF 150.0 m), which included interest income of CHF 5.0 million, interest expense of CHF 1.4 million, a non-cash charge related to the Convertible Bond of CHF 0.4 million, other financial expense related to currency valuations CHF 17.6 million and an income tax expense of CHF 4.9 million.

Balance sheet



Total assets of Actelion at 31 March 2008 were CHF 1.660 billion.

Financial Overview

In CHF thousands	Result		in %
	Q1 2008	Q1 2007	
Net Revenues	321,576	290,439	11
Operating Expenses	253,814	441,912	(43)
Operating Income	67,762	(151,473)	-
Cash EBIT	99,808	101,288	(1)
Net Income	48,335	(149,998)	-
Diluted EPS in CHF	0.39	(1.29)	-
No of shares in calculation	123.357 m	116.635 m	

The full financial statements can be found on <http://www.actelion.com>

Share price development over 12 months



Actelion Ltd – shares at a glance

The registered shares of Actelion Ltd were first listed on the SWX New Market on April 6, 2000 (symbol: ATLN). A total of 1,000,000 primary shares were placed at the company's Initial Public Offering (IPO), at a price of CHF 260 per share, raising CHF 246.6 million.

On 22 November 2006, Actelion Finance SCA, Luxembourg issued CHF 460 million of senior convertible bonds due 2011 unconditionally and irrevocably guaranteed by Actelion Ltd, Allschwil, Switzerland. The bonds have a coupon of zero percent and an annual yield to maturity of zero percent. The conversion price is CHF 270.84. On or after 30 June 2007 and until the 30th trading day prior to the maturity date on 22 November 2011, each Bond in the denomination of CHF 5,000 is convertible free of charge into cash up to the principal amount and any conversion value above the principal amount may be settled, at the option of Actelion, into cash or shares or a combination

thereof. The issue price was set at 100% and the redemption price at 100%. The Bonds are non-callable for life.

On 18 January 2007, Actelion exercised its right to call for an early redemption of the Senior Unsecured Zero Coupon Convertible Bonds due 15 October 2008 issued by Actelion Finance SCA, Luxembourg on 1 October 2003. The redemption date was 19 February 2007. The bonds were fully converted and 937,068 shares were issued.

Actelion Ltd is part of the following indices: SPI, SLI, SMIM, SPIMLC, SPI20, SPISMC, SXXP, SXDP, SBC100, SNSPIX, SMHCAX, SLDI, SXI LIFE SCIENCES and SXI Bio+Medtech.

Actelion is traded under the following symbols: Reuters: ATLN.S/ Bloomberg ATLN.

Key share data

Shares outstanding as of 31.03.2008:	122,910,238
Closing share price as of 31.03.2008:	CHF 54.15
Market capitalization as of 31.03.2008:	CHF 6.66 billion
52 week high:	CHF 71.50
52 week low:	CHF 45.40
YTD price change:	+4 %
Average daily volume:	1.029 million
Free float:	94.7%
Shareholdings as of 31.03.2008	

Number of registered shareholders: 6,917

Major shareholders as per 31.03.2008

Members of the Board of Directors and the AEC	> 5%
BB Biotech Invest SA	> 5%
Fidelity Management & Research Co.	> 5%
Rudolf Maag	> 5%
Actelion Ltd	> 3%
Jean-Paul Clozel	> 3%
MFS Investment Management	> 3%

Disclaimer:

This fact sheet has the sole purpose to provide members of the public with general information about the activities of Actelion Ltd and its associated companies. The forward-looking statements in this fact sheet are based on current expectations and belief of company management, which are subject to numerous risks and uncertainties.

Latest update: April 2008